MCID: ESP024
MIFTS: 64

Esophagitis

Categories: Infectious diseases, Gastrointestinal diseases

Aliases & Classifications for Esophagitis

MalaCards integrated aliases for Esophagitis:

Name: Esophagitis 12 28 51 41 14 69
Acute Esophagitis 12 69

Classifications:



External Ids:

Disease Ontology 12 DOID:11963
ICD10 32 K20 K20.9
ICD9CM 34 530.1 530.10
MeSH 41 D004941
NCIt 46 C9224

Summaries for Esophagitis

MalaCards based summary : Esophagitis, also known as acute esophagitis, is related to peptic esophagitis and gastroesophageal reflux, and has symptoms including pain in esophagus (finding) An important gene associated with Esophagitis is CCL26 (C-C Motif Chemokine Ligand 26), and among its related pathways/superpathways are ERK Signaling and TGF-Beta Pathway. The drugs Budesonide and Omeprazole have been mentioned in the context of this disorder. Affiliated tissues include lung, lymph node and endothelial, and related phenotypes are growth/size/body region and homeostasis/metabolism

Wikipedia : 72 Esophagitis (or oesophagitis) is an inflammation of the esophagus. The prefix esophag/o refers to the... more...

Related Diseases for Esophagitis

Diseases in the Esophagitis family:

Bacterial Esophagitis Viral Esophagitis

Diseases related to Esophagitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 855)
# Related Disease Score Top Affiliating Genes
1 peptic esophagitis 33.5 CXCL8 CYP2C19 HRH2 IL1B
2 gastroesophageal reflux 31.3 CCL26 CXCL8 CYP2C19 HRH2 IL1B PTGS2
3 esophagitis, eosinophilic, 1 31.2 CCL11 CCL26 CCR3 DSG1 IL13 IL5
4 esophageal disease 31.1 CCL26 CYP2C19 HRH2 IL13 IL5 PTGS2
5 kaposi sarcoma 31.0 CCR3 CXCL8 IL6 TP53
6 helicobacter pylori infection 30.4 CXCL8 CYP2C19 IL1B
7 pharyngitis 30.4 CXCL8 IL1B PTGS2
8 atrophic gastritis 30.3 CXCL8 IL1B TP53
9 gastritis 30.2 CXCL8 HRH2 IL1B PTGS2
10 acquired immunodeficiency syndrome 30.2 IL1B IL6 TP53
11 chagas disease 30.1 CXCL8 IL1B IL6 TGFB1
12 laryngitis 30.1 HRH2 IL1B IL6 TGFB1
13 duodenal ulcer 30.0 CXCL8 CYP2C19 HRH2 IL1B
14 prostatitis 30.0 CXCL8 IL1B IL6 TGFB1
15 interstitial lung disease 29.8 CXCL8 IL1B IL6 TGFB1
16 acute respiratory distress syndrome 29.8 CXCL8 IL1B IL6
17 oral squamous cell carcinoma 29.7 CXCL8 PTGS2 TP53
18 gingivitis 29.7 CXCL8 IL1B IL6
19 osteomyelitis 29.7 CXCL8 IL1B IL6
20 gastric ulcer 29.7 CXCL8 CYP2C19 HRH2 IL1B PTGS2
21 ureteral obstruction 29.6 PTGS2 TGFB1 TP53
22 vaginitis 29.6 CXCL8 IL1B IL6
23 squamous cell carcinoma, head and neck 29.6 CXCL8 PTGS2 TGFB1 TP53
24 peritonitis 29.5 CXCL8 IL1B IL6
25 ige responsiveness, atopic 29.4 IL13 IL5 TSLP
26 meningitis 29.4 CXCL8 IL1B IL6
27 periodontitis 29.4 CXCL8 IL1B IL6
28 lung disease 29.4 CXCL8 IL13 IL1B IL5 TGFB1
29 pulmonary fibrosis, idiopathic 29.4 CXCL8 IL13 IL1B TGFB1
30 pneumoconiosis 29.4 CXCL8 IL1B IL6 TGFB1
31 gastroenteritis 29.2 CCL11 CXCL8 IL1B IL5 IL6
32 interstitial cystitis 29.2 CXCL8 IL6 TRPV1
33 arthritis 29.2 CXCL8 IL1B IL6 PTGS2
34 peptic ulcer disease 29.1 CXCL8 CYP2C19 HRH2 IL1B PTGS2
35 rheumatoid arthritis 29.0 CXCL8 IL1B IL6 PTGS2 TGFB1
36 dyspepsia 28.9 CXCL8 CYP2C19 HRH2 PTGS2 TRPV1
37 cystitis 28.8 CXCL8 IL6 PTGS2 TP53 TRPV1
38 pneumonia 28.8 CCL11 CXCL8 IL13 IL1B IL5 IL6
39 autoimmune disease 28.7 DSG1 IL1B IL5 IL6
40 vulvovaginitis 28.5 CCL11 CXCL8
41 hypereosinophilic syndrome 28.4 CCL11 CXCL8 IL13 IL5
42 eosinophilic gastritis 28.4 CCL11 CCL26 IL13 IL5
43 bullous pemphigoid 28.4 CCL11 DSG1 IL5
44 keratoconjunctivitis 28.0 CCL11 CXCL8 IL13 IL5 TSLP
45 allergic asthma 28.0 CCL11 CXCL8 IL13 IL5 TSLP
46 allergic hypersensitivity disease 27.8 CCL11 CCR3 IL13 IL5 TSLP
47 malaria 27.6 CCL11 CXCL8 IL13 IL1B IL5 IL6
48 inflammatory bowel disease 27.4 CCL11 CXCL8 IL13 IL1B IL5 IL6
49 asthma 26.0 CCL11 CCL26 CCR3 CXCL8 HRH2 IL13
50 esophageal cancer 12.5

Comorbidity relations with Esophagitis via Phenotypic Disease Network (PDN): (show top 50) (show all 112)


Active Peptic Ulcer Disease Acute Cystitis
Acute Maxillary Sinusitis Acute Pancreatitis
Alcoholic Gastritis Allergic Rhinitis
Anxiety Aortic Valve Disease 1
Atrophic Gastritis Basilar Artery Insufficiency
Benign Essential Hypertension Bronchiectasis
Bronchitis Bronchopneumonia
Cerebrovascular Disease Cholecystitis
Cholestasis Chronic Intestinal Vascular Insufficiency
Chronic Kidney Failure Chronic Maxillary Sinusitis
Chronic Myocardial Ischemia Chronic Pulmonary Heart Disease
Chronic Rhinitis Chylomicron Retention Disease
Conn's Syndrome Conversion Disorder
Cystitis Deficiency Anemia
Dependent Personality Disorder Dermatomycosis
Diabetic Polyneuropathy Duodenitis
Dyskinesia of Esophagus Dysthymic Disorder
Esophageal Cancer Esophageal Candidiasis
Esophageal Disease Esophageal Varix
First-Degree Atrioventricular Block Gallbladder Disease
Gastrin Secretion Abnormality Gastritis, Familial Giant Hypertrophic
Gastroesophageal Reflux Generalized Anxiety Disorder
Generalized Atherosclerosis Heart Disease
Hepatitis Hyperlipoproteinemia, Type Iv
Hyperlipoproteinemia, Type V Hypertension, Essential

Graphical network of the top 20 diseases related to Esophagitis:



Diseases related to Esophagitis

Symptoms & Phenotypes for Esophagitis

UMLS symptoms related to Esophagitis:


pain in esophagus (finding)

MGI Mouse Phenotypes related to Esophagitis:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.17 IL13 PTGS2 IL1B IL5 DSG1 IL6
2 homeostasis/metabolism MP:0005376 10.15 IL13 PTGS2 IL1B IL5 CCR3 HRH2
3 hematopoietic system MP:0005397 10.14 IL13 PTGS2 IL1B IL5 CCL11 CCR3
4 immune system MP:0005387 10.1 PTGS2 IL1B SOD2 IL5 CCL11 CCR3
5 digestive/alimentary MP:0005381 10.06 IL13 PTGS2 IL5 IL6 HRH2 TP53
6 adipose tissue MP:0005375 10.02 PTGS2 DSG1 IL6 TP53 TRPV1 SOD2
7 integument MP:0010771 9.96 IL1B SOD2 IL6 DSG1 IL13 PTGS2
8 liver/biliary system MP:0005370 9.7 PTGS2 IL5 IL6 TP53 TRPV1 SOD2
9 neoplasm MP:0002006 9.56 PTGS2 IL1B SOD2 IL5 IL6 TP53
10 respiratory system MP:0005388 9.28 PTGS2 IL5 CCL11 CCR3 IL6 IL13

Drugs & Therapeutics for Esophagitis

Drugs for Esophagitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 263)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Budesonide Approved Phase 4,Phase 3,Phase 2 51333-22-3 5281004 63006
2
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 73590-58-6 4594
3
Domperidone Approved, Investigational, Vet_approved Phase 4 57808-66-9 3151
4
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
5
Pantoprazole Approved Phase 4,Phase 3,Phase 2 102625-70-7 4679
6
Dexlansoprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 138530-94-6, 103577-45-3 9578005
7
Lansoprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 103577-45-3 3883
8
Rabeprazole Approved, Investigational Phase 4,Phase 3,Phase 2 117976-89-3 5029
9
Esomeprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 161796-78-7, 119141-88-7 9579578 4594
10
Pemetrexed Approved, Investigational Phase 4,Phase 3,Phase 2 150399-23-8, 137281-23-3 60843 446556
11
Ranitidine Approved Phase 4,Phase 1 66357-59-3, 66357-35-5 3001055
12
Trimebutine Approved Phase 4 39133-31-8
13
Verapamil Approved Phase 4 52-53-9 2520
14
Menthol Approved Phase 4,Phase 3 2216-51-5 16666
15
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 59-30-3 6037
16
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2 58-05-9 143 6006
17 Rebamipide Investigational Phase 4 90098-04-7
18
Maleic acid Experimental Phase 4 110-16-7 444266
19 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2,Phase 1
20 Cromolyn Sodium Phase 4
21 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1
22 Anti-Allergic Agents Phase 4,Phase 3,Phase 2,Phase 1
23 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
24 Autonomic Agents Phase 4,Phase 3,Phase 2
25 Bronchodilator Agents Phase 4,Phase 3,Phase 2
26 Dermatologic Agents Phase 4,Phase 3,Phase 2
27
Fluticasone Phase 4,Phase 3,Phase 2 80474-14-2, 90566-53-3 22833648 62924
28 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
29 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
30 Hormones Phase 4,Phase 3,Phase 2,Phase 1
31 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
32 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
33 Antacids Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
34 Antiemetics Phase 4
35 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Dopamine Agents Phase 4
37 Dopamine Antagonists Phase 4
38 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
39 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
40 Proton pump inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
41 Protective Agents Phase 4,Phase 2,Phase 1
42 Omeprazole, sodium bicarbonate drug combination Phase 4
43 Antioxidants Phase 4,Phase 2,Phase 1
44 Pepsin A Phase 4
45
Bilirubin Phase 4 635-65-4 5280352
46 Folic Acid Antagonists Phase 4,Phase 3,Phase 2
47 N-Methylaspartate Phase 4
48 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
49 Vitamin B Complex Phase 4,Phase 3,Phase 2
50 Ranitidine bismuth citrate Phase 4,Phase 1

Interventional clinical trials:

(show top 50) (show all 380)

# Name Status NCT ID Phase Drugs
1 Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis Unknown status NCT02371941 Phase 4 oral cromolyn sodium;Placebo
2 Dietetic Versus Topical Steroids for Pediatric Eosinophilic Esophagitis Unknown status NCT01846962 Phase 4 Budesonide;Fluticasone
3 Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Wu-Chu-Yu Tang on Gastroesophageal Reflux Disease (GERD) Unknown status NCT01822106 Phase 4
4 Research of Efficient Use of Omeprazole in Combination With Domperidone in Gastroesophageal Reflux Disease of Mild to Moderate Severity Unknown status NCT02140073 Phase 4 omeprazole+domperidone SR;omeprazole
5 Intravenous (IV) Pantoprazole in Erosive Esophagitis Completed NCT00133770 Phase 4 pantoprazole
6 An Efficacy Study to Compare the Treatment Effects of Rabeprazole and Lansoprazole Depending on the Genotyping of CYP2C19 in Treating Reflux Esophagitis Completed NCT01008696 Phase 4 Rabeprazole;Lansoprazole
7 Rate of Complete Symptom Relief, Prevention of Symptom Relapse: Grades A and B Esophagitis of Esomeprazole Therapy Completed NCT01874535 Phase 4 Esomeprazole 40 mg
8 A Multicenter, Randomized, Double Blind, Double Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment With Esomeprazole Magnesium (40mg qd) to Lansoprazole (30mg qd) for the Healing of Erosive Esophagitis in Patients With Moderate or Severe Completed NCT00641602 Phase 4 Esomeprazole;Lansoprazole
9 Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study Completed NCT00693225 Phase 4 Omeprazole/sodium bicarbonate
10 Vonoprazan Study of Investigating the Effect on Sleep Disturbance Associated With Reflux Esophagitis- Exploratory Evaluation Completed NCT03116841 Phase 4 Vonoprazan
11 NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis Completed NCT00206180 Phase 4 esomeprazole magnesium (oral medication)
12 The Study to Evaluate Efficacy and Safety of Newrabell® Tab.(Rabeprazole Sodium) 10mg b.i.d in Refractory GERD Completed NCT01860482 Phase 4 Newrabell® Tablet 10mg
13 A Study to Evaluate REbamiPide as an Adjuvant Regimen to Heal erosIve Reflux Esophagitis Completed NCT02755753 Phase 4 Lansoprazole;Rebamipide;Rebamipide-placebo
14 Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of the Remission Rates of Once Daily Treatment With Esomeprazole 20mg and Lansoprazole 15mg for 6 Months in Patients Whose EE Has Been Healed Completed NCT00644735 Phase 4 Esomeprazole;Lansoprazole
15 Esomeprazole for Treatment of GERD in Pediatric Patients Completed NCT00228527 Phase 4 Esomeprazole (Nexium)
16 An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD) Completed NCT00242736 Phase 4 Esomeprazole
17 Role of Pepsin Assay in Wheezy Infants Completed NCT02685436 Phase 4 Omeprazole and domperidone
18 To Assess the Efficacy of Esomeprazole 20mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole Completed NCT01397084 Phase 4 esomeprazole 20 mg
19 Dexlansoprazole in Asian Participants With Gastroesophageal Reflux Disease Completed NCT02351960 Phase 4 Dexlansoprazole
20 The Prospective Study on the Effect of Ilaprazole in Non-erosive Reflux Disease Patients; Focused on Histologic Findings and Inflammatory Biomarker Completed NCT02666976 Phase 4 Ilaprazole
21 An Open-Label Trial of Dexlansoprazole 60mg for the Relief of Heartburn During the Fasting Month of Ramadan Completed NCT03079050 Phase 4 Dexlansoprazole 60 MG
22 Study to Assess Management Strategies for the Use of Esomeprazole (Nexium) in Helicobacter Pylori Infected Patients Completed NCT00574925 Phase 4 Esomeprazole
23 A Study of Rabeprazole and Pantoprazole on Stomach Acid and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease (GERD) and a History of Nighttime Heartburn Completed NCT00237367 Phase 4 rabeprazole and pantoprazole
24 Do Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux Predict Response to Treatment? Completed NCT00444145 Phase 4 Prevacid
25 Nissen and Gastroplasty in Gastroesophageal Reflux Disease (GERD) Completed NCT00872755 Phase 4
26 Chemotherapy for Patients With Non-Small Cell Lung Cancer Completed NCT00380718 Phase 4 pemetrexed
27 Trimebutine Maleate Combined With Rabeprazole in Patients With Grade A or B Reflux Esophagitis Whose Symptoms Refractory to Rabeprazole Recruiting NCT02986685 Phase 4 Trimebutine Maleate;rabeprazole
28 Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis Recruiting NCT02019758 Phase 4 Oral Viscous Budesonide;Fluticasone MDI;Placebo slurry;Placebo inhaler
29 Prevention of Silent Cerebral Thromboembolism by Oral Anticoagulation With Dabigatran After Pulmonary Vein Isolation for Atrial Fibrillation Recruiting NCT02067182 Phase 4 Dabigatran
30 Vonoprazan Study in Patients With Erosive Esophagitis to Evaluate Long-term Safety Active, not recruiting NCT02679508 Phase 4 Vonoprazan;Lansoprazole
31 Transoral Incisionless Fundoplication (TIF) Versus Sham for Treatment of Gastroesophageal Reflux Disease (GERD) Active, not recruiting NCT01110811 Phase 4
32 Treatment Effect Between Dexlansoprazole and Double-dose Lansoprazole in Obesity Patients With Reflux Esophagitis Enrolling by invitation NCT02759393 Phase 4 Dexlansoprazole;Lansoprazole
33 The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors Terminated NCT01404832 Phase 4 Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms
34 Lansoprazole Preventing Gastroduodenal Stress Ulcerations Terminated NCT00220909 Phase 4 Lansoprazole
35 Dexilant Treatment in Gastrointestinal Reflux Disease (GERD Related Non Cardiac Chest Pain Withdrawn NCT01637571 Phase 4 Dexilant;Dexilant Placebo
36 Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone Unknown status NCT01702701 Phase 3 Montelukast;Fluticasone
37 A Trial of Reconstruction After Distal Gastrectomy for Gastric Cancer Unknown status NCT01065688 Phase 3
38 Endoscopic Fundoplication Versus Proton Pump Inhibitors for GERD Treatment Unknown status NCT00857597 Phase 3 Proton Pump Inhibitors; active control
39 Study to Confirm the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis Completed NCT03006874 Phase 3 CJ-12420 100mg QD;Esomeprazole 40mg;CJ-12420 50mg QD
40 Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis Completed NCT02456935 Phase 3 CJ-12420 100 mg QD;Esomeprazole 40 mg QD
41 Reflux Esophagitis Phase III Study (Initial Treatment) Completed NCT00633932 Phase 3 Esomeprazole;Esomeprazole;Omeprazole
42 Reflux Esophagitis Phase III Study (Maintenance Treatment) Completed NCT00634114 Phase 3 Esomeprazole;Esomeprazole;Omeprazole
43 Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Erosive Esophagitis Completed NCT01452698 Phase 3 TAK-438;Placebo;Lansoprazole;Placebo
44 Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Maintenance Treatment of Healed Erosive Esophagitis Completed NCT01459367 Phase 3 TAK-438;TAK-438;Lansoprazole
45 Efficacy and Safety of Oral Once-Daily Vonoprazan (TAK-438) in Participants With Erosive Esophagitis Completed NCT02388724 Phase 3 Vonoprazan;Lansoprazole;Vonoprazan Placebo;Lansoprazole Placebo
46 Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis Completed NCT00251719 Phase 3 Dexlansoprazole MR;Dexlansoprazole MR;Lansoprazole
47 Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis Completed NCT00251693 Phase 3 Dexlansoprazole MR;Dexlansoprazole MR;Lansoprazole
48 Efficacy and Safety of Dexlansoprazole MR Compared to Placebo on Maintaining Healing in Subjects With Healed Erosive Esophagitis Completed NCT00321737 Phase 3 Dexlansoprazole MR;Dexlansoprazole MR;Placebo
49 Efficacy and Safety of Dexlansoprazole MR on Maintaining Healing in Subjects With Healed Erosive Esophagitis Completed NCT00255164 Phase 3 Dexlansoprazole MR;Dexlansoprazole MR;Placebo
50 Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis Completed NCT00255151 Phase 3 Dexlansoprazole MR;Dexlansoprazole MR;Placebo

Search NIH Clinical Center for Esophagitis

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: esophagitis

Genetic Tests for Esophagitis

Genetic tests related to Esophagitis:

# Genetic test Affiliating Genes
1 Esophagitis 28

Anatomical Context for Esophagitis

MalaCards organs/tissues related to Esophagitis:

38
Lung, Lymph Node, Endothelial, Testes, Colon, Liver, Bone

Publications for Esophagitis

Articles related to Esophagitis:

(show top 50) (show all 9060)
# Title Authors Year
1
Early diagnostic potential of<i>APC</i>hypermethylation in esophageal cancer. ( 29440928 )
2018
2
Determinant factors of quality of life in adult patients with eosinophilic esophagitis. ( 29435312 )
2018
3
Eosinophilic fasciitis associated with Raynaud's phenomenon, esophageal dysmotility, positive antinuclear antibody and anti-neutrophil cytoplasmic antibody. ( 29393078 )
2018
4
Salvage Surgery for Esophageal Cancer: How to Improve Outcomes? ( 29417405 )
2018
5
Comment on: Clinical Characteristics of Severe Erosive Esophagitis among Patients with Erosive Esophagitis: A Case-control Study. ( 29434125 )
2018
6
Association between Minimal Change Esophagitis and Gastric Dysmotility: A Single-Center Electrogastrography and Endoscopy Study in Children. ( 29383301 )
2018
7
Clinical Translation of Tethered Confocal Microscopy Capsule for Unsedated Diagnosis of Eosinophilic Esophagitis. ( 29422678 )
2018
8
The Effect of Race in Patients with Achalasia Diagnosed With High-Resolution Esophageal Manometry. ( 29406039 )
2018
9
Comparative effectiveness of upfront esophagectomy versus induction chemoradiation in clinical stage T2N0 esophageal cancer: A decision analysis. ( 29428700 )
2018
10
Gastroesophageal reflux symptoms are not sufficient to guide esophageal function testing in lung transplant candidates. ( 29444329 )
2018
11
Overexpression of F-box only protein 31 predicts poor prognosis and deregulates p38I+- and JNK-mediated apoptosis in esophageal squamous cell carcinoma. ( 28905993 )
2018
12
Minimally invasive esophagectomy may contribute to long-term respiratory function after esophagectomy for esophageal cancer. ( 29444214 )
2018
13
Is eosinophilic esophagitis an equivalent of pollen allergic asthma? Analysis of biopsies and therapy guided by component resolved diagnosis. ( 29338961 )
2018
14
The Author's Reply: Comment on: Clinical Characteristics of Severe Erosive Esophagitis among Patients with Erosive Esophagitis: A Case-control Study. ( 29434142 )
2018
15
Role of ALDH1 in the prognosis of esophageal cancer and its relationship with tumor microenvironment. ( 28888039 )
2018
16
Prolonged Time to Diagnosis of Eosinophilic Esophagitis Despite Increasing Knowledge of the Disease. ( 29374615 )
2018
17
Neoadjuvant Treatments for Locally Advanced, Resectable Esophageal Cancer: A Network Meta-Analysis. ( 29441562 )
2018
18
Rationale and design of the VISION study: a randomized, open-label study to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive esophagitis. ( 29416369 )
2018
19
Eosinophilic Esophagitis Through the Flexible Endoscope and the Lens of a Photographer in the Amazon. ( 29427131 )
2018
20
Rising incidence and prevalence of adult eosinophilic esophagitis in midwestern Spain (2007-2016). ( 29435311 )
2018
21
Laryngotracheal anomalies associated with esophageal atresia: importance of early diagnosis. ( 29299746 )
2018
22
The ability of silver(I) thiocyanate 4-methoxyphenyl phosphine to induce apoptotic cell death in esophageal cancer cells is correlated to mitochondrial perturbations. ( 29430579 )
2018
23
Hot Tea and Esophageal Cancer. ( 29404600 )
2018
24
Basic Knowledge of Tracheoesophageal Fistula and Esophageal Atresia. ( 29373345 )
2018
25
Per-oral endoscopic myotomy for esophageal achalasia in a case of Allgrove syndrome. ( 29383495 )
2018
26
Esophageal Squamous Cell Papillomatosis Arising in Focal Dermal Hypoplasia in a Three-year-old Girl. ( 29373440 )
2018
27
Surgical management of esophageal sarcoma: a multicenter European experience. ( 29444281 )
2018
28
Whole exome sequencing identifies a mutation in EYA1 and GLI3 in a patient with branchioa89otic syndrome and esophageal atresia: Coincidence or a digenic mode of inheritance? ( 29257230 )
2018
29
Eosinophilic Esophageal Myositis a Plausible Cause of Histological Changes of Primary Jackhammer Esophagus: A Case Report. ( 29311727 )
2018
30
Combined and Alternating Topical Steroids and Food Elimination Diet for the Treatment of Eosinophilic Esophagitis. ( 29380175 )
2018
31
Efficacy comparison of transcervical video-assisted mediastinoscopic lymphadenectomy combined with left transthoracic esophagectomy versus right transthoracic esophagectomy for esophageal cancer treatment. ( 29426329 )
2018
32
Negative regulation of lncRNA GAS5 by miR-196a inhibits esophageal squamous cell carcinoma growth. ( 29170131 )
2018
33
SLC52A3 expression is activated by NF-I_B p65/Rel-B and serves as a prognostic biomarker in esophageal cancer. ( 29428966 )
2018
34
Is eosinophilic esophagitis a member of the atopic march? ( 29413330 )
2018
35
Well-Differentiated Liposarcoma (Atypical Lipomatous Tumor) Presenting as an Esophageal Polyp. ( 29349606 )
2018
36
Eosinophilic esophagitis and esophageal atresia: coincidence or causality? ( 29333824 )
2018
37
Outcomes of abdominal esophageal cancer patients who were treated with esophagectomy. ( 29435289 )
2018
38
Transgastric Endoscopic Submucosal Dissection of Esophageal Cancer with Cervical Stricture. ( 29420854 )
2018
39
Neurodevelopmental outcomes of infants with esophageal atresia and tracheoesophageal fistula. ( 29429769 )
2018
40
<i>Trypanosoma cruzi</i> Detection in Colombian Patients with a Diagnosis of Esophageal Achalasia. ( 29405099 )
2018
41
Characteristics and outcomes of children with ductal-dependent congenital heart disease and esophageal atresia/tracheoesophageal fistula: A multi-institutional analysis. ( 29325785 )
2018
42
Macrophage migration inhibitory factor promotes tumor aggressiveness of esophageal squamous cell carcinoma via activation of Akt and inactivation of GSK3I^. ( 29079416 )
2018
43
High-Resolution Infrared Thermography of Esophageal Temperature During Radiofrequency Ablation of Atrial Fibrillation. ( 29449354 )
2018
44
Understanding fibrosis in eosinophilic esophagitis: Are we there yet? ( 29377264 )
2018
45
A novel method of endoscopic-assisted esophageal clearance in advanced achalasia. ( 29344565 )
2018
46
Role of<i>MLH1</i>methylation in esophageal cancer carcinogenesis and its clinical significance. ( 29440913 )
2018
47
Integrin I+M activation and upregulation on esophageal eosinophils and periostin-mediated eosinophil survival in eosinophilic esophagitis. ( 29424023 )
2018
48
Cervicothoracoscopic Approach for Esophageal Cancer in a Patient with Right-Sided Aortic Arch. ( 29411200 )
2018
49
Prevalence of Laryngeal Cleft in Pediatric Patients With Esophageal Atresia. ( 29270628 )
2018
50
Etiological heterogeneity and clinical variability in newborns with esophageal atresia. ( 29373986 )
2018

Variations for Esophagitis

Expression for Esophagitis

Search GEO for disease gene expression data for Esophagitis.

Pathways for Esophagitis

Pathways related to Esophagitis according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.81 CCL11 CCL26 CCR3 CXCL8 IL13 IL1B
2
Show member pathways
13.54 CCL11 CCL26 CXCL8 IL13 IL1B IL5
3
Show member pathways
13.41 CCL11 CCL26 CCR3 CXCL8 IL13 IL1B
4
Show member pathways
13.38 CCL11 CCL26 CCR3 CXCL8 IL13 IL1B
5
Show member pathways
13.36 CCL11 CXCL8 IL13 IL1B IL5 IL6
6
Show member pathways
13.28 CCL11 CCL26 CCR3 CXCL8 IL13 IL1B
7 12.86 CXCL8 IL13 IL5 IL6 PTGS2 TGFB1
8
Show member pathways
12.86 CCL11 CXCL8 IL13 IL1B IL5 IL6
9
Show member pathways
12.79 CXCL8 IL13 IL1B IL6 TP53
10
Show member pathways
12.61 CCR3 CXCL8 IL6 PTGS2 TGFB1 TP53
11
Show member pathways
12.6 IL13 IL1B IL5 IL6 TGFB1
12
Show member pathways
12.52 CXCL8 IL1B IL6 TGFB1
13
Show member pathways
12.44 IL13 IL1B IL5 TP53
14
Show member pathways
12.42 IL1B IL5 IL6 TGFB1
15
Show member pathways
12.37 IL13 IL5 IL6 TSLP
16
Show member pathways
12.37 IL1B IL6 PTGS2 SOD2 TP53
17
Show member pathways
12.34 CCL11 CCL26 CCR3 CXCL8
18
Show member pathways
12.31 CXCL8 IL1B IL6 PTGS2 TP53
19
Show member pathways
12.31 CCL11 CXCL8 IL13 IL1B IL5 IL6
20
Show member pathways
12.2 CCL11 CXCL8 IL1B IL6
21 12.2 IL6 PTGS2 TGFB1 TP53
22 12.19 CXCL8 IL13 IL1B IL6
23 12.17 CXCL8 IL6 TGFB1 TP53
24
Show member pathways
12.17 CXCL8 IL13 IL1B IL5 IL6
25
Show member pathways
12.06 IL13 IL1B IL5 TP53
26
Show member pathways
12.02 CCL11 CCL26 CCR3 CXCL8
27 12.01 CXCL8 IL1B IL6 PTGS2 TGFB1 TP53
28 11.97 CXCL8 IL1B IL6 TGFB1 TP53
29 11.95 CXCL8 IL1B IL6 TGFB1
30 11.94 IL1B IL6 PTGS2
31 11.93 CXCL8 IL1B IL6 TGFB1
32
Show member pathways
11.92 IL1B IL6 TGFB1
33 11.9 CXCL8 IL1B IL6 TGFB1
34 11.88 IL1B IL5 IL6
35 11.87 CXCL8 IL1B PTGS2
36
Show member pathways
11.86 CXCL8 IL6 TGFB1
37
Show member pathways
11.85 IL1B IL6 TGFB1
38 11.84 CXCL8 IL13 IL5 IL6 TP53
39 11.83 IL13 IL1B IL5 TSLP
40 11.82 CXCL8 IL1B IL6
41
Show member pathways
11.76 CXCL8 IL5 PTGS2
42 11.76 CXCL8 IL1B IL6
43 11.75 IL1B IL6 TGFB1
44
Show member pathways
11.72 CXCL8 IL1B IL6 PTGS2
45 11.69 IL5 IL6 TGFB1
46 11.67 CCL11 CCL26 IL5
47 11.61 CXCL8 IL1B IL6
48 11.61 CCL11 CXCL8 IL13 IL1B IL6 PTGS2
49 11.6 CXCL8 IL6 PTGS2 TGFB1 TP53
50 11.58 CXCL8 IL1B IL6 TGFB1

GO Terms for Esophagitis

Cellular components related to Esophagitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 CCL11 CCL26 CXCL8 IL13 IL1B IL5
2 extracellular space GO:0005615 9.28 CCL11 CCL26 CXCL8 IL13 IL1B IL5

Biological processes related to Esophagitis according to GeneCards Suite gene sharing:

(show all 42)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 9.97 IL6 PTGS2 TGFB1 TP53 TRPV1
2 response to lipopolysaccharide GO:0032496 9.93 IL13 IL1B PTGS2 SOD2
3 aging GO:0007568 9.92 PTGS2 SOD2 TGFB1 TP53
4 chemotaxis GO:0006935 9.89 CCL11 CCL26 CCR3 CXCL8
5 positive regulation of DNA binding transcription factor activity GO:0051091 9.86 IL1B IL5 IL6
6 positive regulation of angiogenesis GO:0045766 9.86 CCL11 CCR3 CXCL8 IL1B
7 positive regulation of cell migration GO:0030335 9.85 CCL11 CCL26 IL1B SOD2 TGFB1
8 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.84 IL6 PTGS2 TGFB1
9 cellular response to tumor necrosis factor GO:0071356 9.84 CCL11 CCL26 CXCL8 TRPV1
10 movement of cell or subcellular component GO:0006928 9.83 CXCL8 IL13 PTGS2
11 protein homotetramerization GO:0051289 9.83 SOD2 TP53 TRPV1
12 cellular response to interleukin-1 GO:0071347 9.83 CCL11 CCL26 CXCL8
13 positive regulation of endothelial cell proliferation GO:0001938 9.82 CCL11 CCL26 CCR3
14 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.81 IL13 IL6 TSLP
15 positive regulation of smooth muscle cell proliferation GO:0048661 9.81 IL13 IL6 PTGS2
16 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.8 IL5 IL6 TGFB1 TP53
17 negative regulation of cell proliferation GO:0008285 9.8 CXCL8 IL1B IL6 PTGS2 SOD2 TGFB1
18 negative regulation of fat cell differentiation GO:0045599 9.78 IL6 SOD2 TGFB1
19 cellular response to mechanical stimulus GO:0071260 9.78 IL13 IL1B PTGS2 TGFB1
20 positive regulation of interleukin-6 production GO:0032755 9.77 IL1B IL6 TSLP
21 cellular response to heat GO:0034605 9.76 PTGS2 TP53 TRPV1
22 immune response GO:0006955 9.76 CCL11 CCL26 CXCL8 HRH2 IL13 IL1B
23 monocyte chemotaxis GO:0002548 9.75 CCL11 CCL26 IL6
24 chemokine-mediated signaling pathway GO:0070098 9.73 CCL11 CCL26 CCR3 CXCL8
25 response to organonitrogen compound GO:0010243 9.72 PTGS2 TP53 TRPV1
26 neutrophil chemotaxis GO:0030593 9.71 CCL11 CCL26 CXCL8 IL1B
27 positive regulation of vascular endothelial growth factor production GO:0010575 9.69 IL1B PTGS2 TGFB1
28 microglial cell activation GO:0001774 9.68 IL13 TRPV1
29 cellular response to ATP GO:0071318 9.68 PTGS2 TRPV1
30 positive regulation of chemotaxis GO:0050921 9.68 CCL26 TGFB1
31 positive regulation of immunoglobulin secretion GO:0051024 9.67 IL5 IL6
32 positive regulation of histone deacetylation GO:0031065 9.67 TGFB1 TP53
33 positive regulation of nitric oxide biosynthetic process GO:0045429 9.67 IL1B PTGS2 SOD2 TRPV1
34 response to manganese ion GO:0010042 9.65 PTGS2 SOD2
35 fever generation GO:0001660 9.62 IL1B TRPV1
36 response to radiation GO:0009314 9.62 CCL11 PTGS2 SOD2 TGFB1
37 positive regulation of fever generation GO:0031622 9.61 IL1B PTGS2
38 regulation of receptor activity GO:0010469 9.61 CCL11 CCL26 CXCL8 IL13 IL1B IL5
39 inflammatory response GO:0006954 9.36 CCL11 CCL26 CCR3 CXCL8 IL13 IL1B
40 positive regulation of transcription, DNA-templated GO:0045893 10.08 IL1B IL5 IL6 TGFB1 TP53
41 negative regulation of apoptotic process GO:0043066 10.06 IL6 PTGS2 SOD2 TP53 TSLP
42 positive regulation of cell proliferation GO:0008284 10 IL1B IL5 IL6 PTGS2 TGFB1 TSLP

Molecular functions related to Esophagitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.55 CYP2C19 PTGS2 SOD2 TGFB1 TP53
2 chemokine activity GO:0008009 9.43 CCL11 CCL26 CXCL8
3 cytokine activity GO:0005125 9.28 CCL11 CCL26 CXCL8 IL13 IL1B IL5
4 CCR3 chemokine receptor binding GO:0031728 8.96 CCL11 CCL26

Sources for Esophagitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....